Autologous stem cell transplant (ASCT)
Autologous stem cell transplant (ASCT) is a medical procedure with 8 clinical trials. Currently 4 active trials ongoing. Historical success rate of 33.3%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
25.0%
1 of 4 finished
75.0%
3 ended early
4
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma
Tinostamustine Conditioning and Autologous Stem Cell
Clinical Trials (8)
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma
Tinostamustine Conditioning and Autologous Stem Cell
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
All 8 trials loaded
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 8